Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC
Clinical Lung Cancer · 2024
DOI: 10.1016/j.cllc.2023.08.012 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Kevin Lu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Diego, La Jolla, CA. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Acrylamides, Aniline Compounds. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California, San Diego, La Jolla, CA.
- Department of Surgery, University of California, San Diego, La Jolla, CA.
- Department of Medicine, University of California, San Diego, La Jolla, CA. Electronic address: hhusain@ucsd.edu.
Zitieren
APA
Lu, K., Woodward, B. D., Boys, J., Onaitis, M., & Husain, H. (2024). Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.08.012
Vancouver
Lu K, Woodward BD, Boys J, Onaitis M, Husain H. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2023.08.012
BibTeX
@article{Lu2024,
author = {Lu, Kevin and Woodward, Brian D and Boys, Joshua and Onaitis, Mark and Husain, Hatim},
title = {Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC},
journal = {Clinical Lung Cancer},
year = {2024},
doi = {10.1016/j.cllc.2023.08.012}
}
EUVIMED